In vitro and in vivo antileishmanial efficacy of a combination therapy of diminazene and artesunate against leishmania donovani in BALB/c mice;Estudo in vitro e in vivo da eficácia anti leishmaniótica de terapêutica combinada de Diminazene e Artesunate contra Leishmania donovani em camundongos Balb/c

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 53, Issue 3, 2011, Pages 129-132

  Mutiso, Muli Joshua ^a,c   Macharia, Chege John ^a   Barasa, Mustafa ^c   Taracha, Evans ^a   Bourdichon, Alain J ^b   Gicheru, Michael M ^c  

^a INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^b TROPMED GMbH   (Germany)

^c KENYATTA UNIVERSITY   (Kenya)

Author keywords

BALB c mice; Diminazene artesunate combination therapy; Leishmania donovani

Indexed keywords

AMPHOTERICIN B; ARTESUNATE; DIMINAZENE; TRYPAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL INFECTION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; MONOTHERAPY; MOUSE; NONHUMAN; PROMASTIGOTE; SPLEEN; SURVIVAL RATE; TREATMENT DURATION;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; ARTEMISININS; DIMINAZENE; DRUG THERAPY, COMBINATION; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LETHAL DOSE 50; MALE; MICE; MICE, INBRED BALB C; PARASITE LOAD;

EID: 79960288073     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652011000300003     Document Type: Article

References (17)

1. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull WHO. 1998;76:25-32.
2. Clement B, Immel M, Raether M. Metabolic N-hydroxylation of diminazene in vitro. Arzneimittelforschung. 1992;42:1497-504.
3. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003;19:502-8.
4. Croft SL, Sundar S, Fairlamb AH. Drug resistance in Leishmaniasis. Clin Microbiol Rev. 2006;19:111-26.
5. Gazanion E, Vergnes B, Seveno M, Garcia D, Oury B, Ait-Oudhia K, et al. In vitro activity of nicotinamide/antileishmanial drug combinations. 2011;60:19-24.
6. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2:494-501.
7. Leon W, Brun R, Krassner SM. Effect of Berenil on growth, mitochondrial DNA and respiration of Leishmania tarentolae promastigotes. J Protozool. 1977;24:444-8.
8. Maarouf M, Adeline MT, Solignac M, Vautrin D, Robert-Gero M. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite. 1998;5:167-73.
9. Macharia JC, Bourdichon AJ, Gicheru MM. Efficacy of Trypan: a diminazene based drug as antileishmanial agent. Acta Trop. 2004;92:267-72.
10. Maltezou CH. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol. 2010;2010:ID 617521. (doi 10.1155/2010/617521).
11. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P. Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet. 2000;39:255-70.
12. Okpekon T, Yolou S, Gleye C, Roblot F, Loiseau PM, Bories C, et al. Antiparasitic activities of medicinal plants used in Ivory Coast. J Ethnopharmacol. 2004;90:91-7.
13. Olliaro PL, Naren NK, Shatasivam K, Mansor SM, Navaratnam V. Pharmacokinetics of artesunate after single oral administration to rats. BMC Pharmacol. 2001;1:12-5.
14. Sacks D & Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2:845-58.
15. Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, Nam J, et al. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis. 2010;4:e675.
16. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull WHO. 2005;83:394-5.
17. World Health Organization. Control of leishmaniasis. Sixtieth World Health Assembly. Document A60/10; 2007.